Patients with cardiovascular disease are at increased risk of subsequent events than individuals without a history of cardiovascular disease despite optimal medical management. Various strategies has been proposed to decrease this increased risk among them increasing HDL.
The HPS2-THRIVE trial examined this question by randomly assigning almost 26,000 individuals with established vascular disease to either placebo or Naicin+laropiprant; a combination that should raise HDL cholesterol. Participants were followed for a median period of 3.9 years. Individuals randomized to the treatment arm had lower LDL (about 10 mg/dL) and higher HDL (about 6 mg.dL) than those who were randomized to placebo. During follow-up, there was no difference in the incidence of major cardiovascular events between the two groups13.2% vs. 13.7%; p = 0.29). On the other hand, individuals randomized to the treatment arm had increased incidence of adverse events such as poor diabetes control or increased incidence of new diagnosis of diabetes.
For now, this trial, puts to rest the use of niacin for decreasing the risk of cardiovascular disease. However, it also raises important questions about the interest in the development of pharmacological therapies directed towards raising HDL-cholesterol. It further questions our current understanding of the role of HDL in the pathogenesis of cardiovascular diseases.
